

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

### ON-MARKET REPURCHASE OF SHARES

This announcement is a voluntary disclosure made by Ascentage Pharma Group International (the “**Company**”) pursuant to Rule 10.06(4)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors of the Company (the “**Board**”) announces that the Company has on November 11, 2021 repurchased an aggregate of 76,800 shares of the Company (the “**Shares**”) pursuant to the general mandate to repurchase shares granted by the shareholders of the Company to the Board at the annual general meeting of the Company held on May 10, 2021 (the “**Repurchase Mandate**”), at the highest price and lowest price of HK\$28.50 and HK\$28.10 per Share, respectively (the “**Share Repurchase**”). The total settlement cost for the Share Repurchase is HK\$2,174,873.63 and was funded from the Company’s existing available cash reserves and free cash flow. The Shares repurchased by the Company under the Share Repurchase represent approximately 0.029% of the total number of Shares in issue as of the date of this announcement immediately prior to the completion of the Share Repurchase, and such Shares repurchased by the Company under the Share Repurchase will be cancelled subsequently. As at the date of this announcement, the Company has repurchased in the open market an aggregate of 1,141,700 Shares under the Repurchase Mandate.

The Share Repurchase was made in accordance with the Listing Rules, and there have been no material changes to the particulars contained in the explanatory statement on the Repurchase Mandate as set out in appendix II to the circular of the Company dated April 9, 2021. The Company may make further repurchases of Shares according to market conditions until the expiry of the Repurchase Mandate, but in any case, subject to the availability of the Repurchase Mandate.

**Shareholders of the Company and investors should note that any repurchase of Shares made pursuant to the Repurchase Mandate will be subject to market conditions and will be at the discretion of the management of the Company. There is no assurance of the timing, quantity or price of any repurchases of Shares or whether the Company will make any further repurchases of Shares at all. Shareholders and investors of the Company should therefore exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, November 11, 2021

*As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director; Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.*